8-K

PRO DEX INC (PDEX)

8-K 2020-02-06 For: 2020-02-06
View Original
Added on April 06, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 6, 2020

PRO-DEX, INC.

(Exact name of registrant as specified in charter)

COLORADO 0-14942 84-1261240
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)

2361 McGaw Avenue

Irvine, California 92614

(Address of principal executive offices, zip code)

(949) 769-3200

(Registrant’s telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
--- ---
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
--- ---
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--- ---

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, no par value PDEX NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ¨

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02.

Results of Operations and Financial Condition.

The information in this Item 2.02 of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

On February 6, 2020 Pro-Dex, Inc. (the “Company”) is issuing a press release announcing its financial performance for the second quarter and six months ended December 31, 2019. A copy of the press release is attached to this Form 8-K as Exhibit 99.1, which is incorporated herein by this reference.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number Description
99.1 Press Release dated February 6, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  February 6, 2020 Pro-Dex, Inc.
By: /s/ Alisha K. Charlton
Alisha K. Charlton
Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number Description
99.1 Press Release dated February 6, 2020.

Press Release

EXHIBIT 99.1

[pdex_ex99z1001.jpg]

Contact:  Richard L. Van Kirk, Chief Executive Officer

(949) 769-3200

For Immediate Release

PRO-DEX, INC. ANNOUNCES FISCAL 2020 SECOND QUARTER

AND SIX-MONTH RESULTS

IRVINE, CA, February 6, 2020 - PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2020 second quarter ended December 31, 2019. The Company also filed its Quarterly Report on Form 10-Q for the second quarter of fiscal year 2020 with the Securities and Exchange Commission today.

Quarter Ended December 31, 2019

Net sales for the three months ended December 31, 2019, increased $1.6 million, or 24%, to $8.0 million from $6.4 million for the three months ended December 31, 2018, due primarily to increased repair revenue generated from our largest customer.

Gross profit for the three months ended December 31, 2019, increased $615,000, or 27%, to $2.9 million from $2.2 million for the same period in fiscal 2019, due to the increase in sales described above and our ability to better absorb and maintain the level of our fixed manufacturing costs.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended December 31, 2019, increased $140,000, or 13%, to $1.2 million compared to the prior fiscal year’s corresponding quarter, reflecting our planned investments in research and development, selling, and general and administrative expenses in an effort to release new products and garner new customer relationships.

Net income for the quarter ended December 31, 2019, was $1.2 million, or $0.31 per diluted share, compared to $1.2 million, or $0.28 per diluted share, for the corresponding quarter in fiscal 2019.

Six Months Ended December 31, 2019

Net sales for the six months ended December 31, 2019, increased $1.9 million, or 14%, to $15.2 million from $13.3 million for the six months ended December 31, 2018, due primarily to increases in repair revenue generated from our largest customer.

Gross profit for the six months ended December 31, 2019, increased $669,000, or 13%, compared to the same period in fiscal 2019 due to the increase in sales described above.

Operating expenses (which include selling, general and administrative, and research and development expenses) for the six months ended December 31, 2019, increased 21% to $2.5 million from $2.1 million in the prior fiscal year’s corresponding period, reflecting our planned investments in research and development, selling, and general and administrative expenses in an effort to release new products and garner new customer relationships.

Net income for the six months ended December 31, 2019 was $2.4 million, or $0.58 per diluted share, compared to $2.5 million, or $0.59 per diluted share, for the corresponding period in fiscal 2019.

CEO Comments

Richard L. (“Rick”) Van Kirk, the Company’s President and Chief Executive Officer, commented, “We are pleased with our second quarter and year-to-date results and our net sales growth.” Mr. Van Kirk continued, “We expect the momentum to continue. Additionally, we are pleased that the private-labeled thoracic driver and related accessories are on track to ship in our third quarter of this fiscal year.”

The amount spent on projects under development as well as the estimated market launch date and estimated future annual revenue is summarized below (in thousands):

Three and Six Months ended December 31, 2019 Three and Six Months ended December 31, 2018 Market Launch Est Annual Revenue
Total Research & Development costs: $ 397 $ 881 $ 326 $ 735
Products in development:
Thoracic Driver $ 17 $ 37 $ 33 $ 107 03/20 $ 4,000
Arthroscopic Shaver^(1)^ 3 11 38 60 06/21 $ 600
ENT Shaver 66 155 01/21 $ 2,000
Arthroscopic Attachment 9 16 ^(2)^ $ 150
CMF Driver 29 46 2 3 06/20 $ 350
Sustaining & Other 282 632 244 549
Total $ 397 $ 881 $ 326 $ 735
Customer CMF Driver ^(3)^ $ 81 $ 181 $ 152 $ 217 06/20 $ 2,500
^(1)^ This project has been internally pushed back to focus on our new internal Pro-Dex branded ENT shaver.
--- ---
^(2)^ Internal development of this project is now complete, but we are looking for the most attractive sales channel.
^(3)^ Costs incurred related to customer contracts are included in costs of sales and deferred costs and are not included in research and development costs.

About Pro-Dex, Inc.:

Pro-Dex, Inc. specializes in the design, development and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also sells rotary air motors to a wide range of industries. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.

Statements herein concerning the Company's plans, growth, and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments, and future performance, (including, but not limited to, estimated product launch dates and estimated future revenue), as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission.

(tables follow)

PRO-DEX, INC.

CONDENSED BALANCE SHEETS

(Unaudited)

(In thousands, except share amounts)

June 30, 2019 ****
ASSETS
Current Assets:
Cash and cash equivalents 6,175 $ 7,742
Investments 3,540 2,649
Accounts receivable, net of allowance for doubtful accounts of 17 and 0 at December 31, 2019 and at June 30, 2019, respectively 2,683 4,100
Deferred costs 492 430
Inventory 7,808 6,239
Prepaid expenses and other current assets 193 623
Total current assets 20,891 21,783
Equipment and leasehold improvements, net 2,768 2,726
Right of use asset, net 3,107
Intangibles, net 145 129
Deferred income taxes, net 163 260
Investments 1,610 582
Other assets 42 40
Total assets 28,726 $ 25,520
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable 1,672 $ 1,996
Accrued expenses 1,287 1,437
Deferred revenue 360 215
Note payable and capital lease obligations 633 622
Total current liabilities 3,952 4,270
Deferred rent 146
Lease liability, net of current portion 2,937
Income taxes payable 352 162
Notes and capital leases payable, net of current portion 3,613 3,934
Total non-current liabilities 6,902 4,242
Total liabilities 10,854 8,512
Shareholders’ equity:
Common shares; no par value; 50,000,000 shares authorized; 3,884,098 and 4,039,491 shares issued and outstanding at December 31, 2019 and June 30, 2019, respectively 13,634 15,815
Accumulated other comprehensive income (loss) 100 (549 )
Retained earnings 4,138 1,742
Total shareholders’ equity 17,872 17,008
Total liabilities and shareholders’ equity 28,726 $ 25,520

All values are in US Dollars.

PRO-DEX, INC.

CONDENSED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE INCOME

(Unaudited)

(In thousands, except per share amounts)

Three Months EndedDecember 31, Six Months EndedDecember 31,
2019 2018 2019 2018
Net sales $ 7,961 $ 6,399 $ 15,201 $ 13,314
Cost of sales 5,097 4,150 9,557 8,339
Gross profit 2,864 2,249 5,644 4,975
Operating (income) expenses:
Selling expenses 135 97 277 130
General and administrative expenses 664 633 1,327 1,197
Gain from disposal of equipment (7 )
Research and development costs 397 326 881 735
Total operating expenses 1,196 1,056 2,485 2,055
Operating income 1,668 1,193 3,159 2,920
Interest expense (63 ) (69 ) (122 ) (89 )
Interest and other income 33 93 68 168
Gain on sale of investments 356 356
Income from operations before income taxes 1,638 1,573 3,105 3,355
Income tax expense (389 ) (394 ) (751 ) (827 )
Net income $ 1,249 $ 1,179 $ 2,354 $ 2,528
Other comprehensive income (loss), net of tax:
Unrealized income (loss) from marketable equity investments 705 (494 ) 649 (349 )
Comprehensive income $ 1,954 $ 685 $ 3,003 $ 2,179
Basic net income per share:
Net income $ 0.32 $ 0.28 $ 0.59 $ 0.59
Diluted net income per share:
Net income $ 0.31 $ 0.28 $ 0.58 $ 0.59
Weighted average common shares outstanding:
Basic 3,950 4,195 3,979 4,263
Diluted 4,053 4,242 4,082 4,303
Common shares outstanding 3,884 4,143 3,884 4,143

PRO-DEX, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

Six Months EndedDecember 31,
2019 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income $ 2,354 $ 2,528
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 282 195
Gain from disposal of equipment (7 )
Share-based compensation 19 18
Non-cash lease expense 22
Amortization of loan fees 4
Gain on sale of investments (356 )
Deferred income taxes 97 742
Bad debt expense (recovery) 17 (13 )
Changes in operating assets and liabilities:
Accounts receivable and other current receivables 1,400 (838 )
Deferred costs (62 ) (143 )
Inventory (1,569 ) (147 )
Prepaid expenses and other assets 430 (46 )
Accounts payable and accrued expenses (771 ) (301 )
Deferred revenue 145 (1 )
Income taxes payable 190 (123 )
Net cash provided by operating activities 2,558 1,508
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of investments (1,271 ) (1,365 )
Purchases of equipment and leasehold improvements (317 ) (540 )
Proceeds from sale of investments 1,905
Proceeds from sale of equipment 7
Increase in intangibles (23 ) (14 )
Net cash used in investing activities (1,611 ) (7 )
CASH FLOWS FROM FINANCING ACTIVITIES:
Repurchases of common stock (2,215 ) (2,560 )
Proceeds from exercise of options and ESPP contributions 15 17
Payment of employee payroll taxes on net issuance of common stock (101 )
Proceeds from Minnesota Bank & Trust long-term debt, net of fees 4,942
Principal payments on notes payable and capital lease (314 ) (116 )
Net cash provided by (used in) financing activities (2,514 ) 2,182
Net increase (decrease) in cash and cash equivalents (1,567 ) 3,683
Cash and cash equivalents, beginning of period 7,742 5,188
Cash and cash equivalents, end of period $ 6,175 $ 8,871